Ipamorelin FAQ
The wording of a question can smuggle in an answer: a useful dose, a predictable effect, an established treatment. Here are the loose ends.
Stations
What does Ipamorelin do for you?
Human intravenous research measured a growth-hormone pulse. The published bowel-recovery trial missed its primary efficacy endpoint. Controlled human results establishing better sleep, recovery, muscle gain or fat loss are absent.
The measured hormone response deserves credit without acquiring benefits the studies never tested. The mechanism is a useful starting point for that distinction.
Does Ipamorelin reduce belly fat or build muscle?
Neither outcome has been established in a controlled human ipamorelin trial. The ferret paper examined reduced weight loss during cisplatin treatment; the rat paper examined bone growth. The orthopaedic review describes the need for clinical evaluation.
A leaner appearance and better recovery also turn up in anecdotal accounts, not clinical evidence. Assembling these very different sources into a body-composition claim none of them tested feels to me like losing the original experiments.
Ipamorelin half-life
The healthy-male-volunteer intravenous study found a terminal half-life of approximately 2 hours and a GH pulse peaking at about 40 minutes. Those measurements describe drug disposition and a hormone response after that route of administration.
They leave the time to a sleep or recovery benefit unanswered. Reports of such changes remain anecdotal. The study amounts page gives the settings behind the timing figures.
Does Ipamorelin increase IGF-1?
Growth hormone can stimulate IGF-1 production. In the adult female rat bone study, total circulating IGF-1 stayed unchanged while longitudinal bone growth increased. That particular animal result leaves the response during prolonged human use unresolved.
The flat blood measurement is one of my favourite complications in this literature. It stops an apparently straightforward hormone story from becoming too tidy.
Why is Ipamorelin being discontinued?
“Discontinued” is a confusing label for a compound with no approved medical indication. The published Phase 2 bowel trial failed to establish efficacy, while later animal and chemistry research continued. The 2024 ferret study is one example of that continuing experimental work.
The status I can defend is specific: unapproved, with a failed published clinical endpoint and unresolved human treatment claims. The FDA and compounding record requires its own explanation.
Appetite and water retention
Increased hunger, puffiness and swelling appear in anecdotal accounts. These are not clinical evidence and cannot establish cause or frequency. Growth-hormone physiology gives fluid retention a plausible context, while ghrelin-receptor biology gives appetite a plausible context.
The effects page discusses the reports and the broader safety concerns together. I give a clinician’s assessment more weight than a forum comparison when a new symptom needs explaining.
What does CJC-1295 and Ipamorelin do?
They stimulate complementary pathways involved in GH release: CJC-1295 through the GHRH pathway and ipamorelin through the ghrelin receptor. The physiology review explains the rationale. Controlled human evidence for sleep, recovery or fat loss from the combination is missing.
Questions about how much to take, where to inject or how to reconstitute the pair therefore have no validated regimen in the human studies. The dosage discussion records study exposures without offering a personal treatment plan.